Detalhe da pesquisa
1.
Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643491
2.
Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.
EJHaem
; 3(3): 794-803, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36051087
3.
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Blood Adv
; 5(20): 4073-4082, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34464973